Hit a GLP-1 Plateau? Here's What's Actually Happening and What to Do

Around month 5 or 6, something shifts. The scale stops moving. You're still taking your injection, still eating less than before, but the number won't budge. Most people assume the medication has stopped working. A significant number come off it entirely at this point, which is almost always the wrong call.

The plateau is not a sign of failure. It is a predictable, documented, biological response. Understanding what's actually happening is the first step to getting past it.

The Plateau Is Built Into the Biology

Set Point Theory

Your body defends a particular weight range. This isn't a metaphor. It's a documented phenomenon involving leptin, ghrelin, and the hypothalamic circuitry that regulates energy balance. When you lose a significant amount of weight, your body responds by increasing hunger hormones, decreasing satiety signalling, and reducing basal metabolic rate, all of which push you back toward your prior weight.

GLP-1 medications blunt this response significantly, which is why they work so much better than diet alone. But they don't eliminate it entirely. As the body adapts, some of the compensatory mechanisms reassert themselves even on medication.

Adaptive Thermogenesis

When you eat less, you burn less. This is called adaptive thermogenesis, and it's one of the most well-studied obstacles in obesity medicine. As you lose weight, your resting metabolic rate decreases more than body composition alone would predict. Your body becomes more fuel-efficient, which sounds virtuous but means the same calorie intake that produced weight loss in month 2 is now maintenance-level in month 6.

When Plateaus Typically Occur

The large STEP trials for semaglutide (Wegovy) give us the most reliable data on plateau timing. In STEP 1, the rate of weight loss slowed substantially between weeks 32 and 68, with most participants reaching maximum weight loss somewhere around week 60.

This means if you plateau at month 6, you're actually on schedule. The question is not why it's happening, but what to do next.

What the STEP 5 Trial Tells Us

STEP 5 is the most important trial for understanding long-term GLP-1 use because it ran for two years rather than the typical 68 weeks. Participants on continuous 2.4mg semaglutide lost an average of 15.2% of body weight over 104 weeks. Crucially, the weight loss trajectory slowed substantially after week 20, but continued, slowly, all the way to week 104.

This tells us two important things. First, the plateau is not a ceiling, it's a slowdown. Second, staying on the medication matters. In the STEP 4 trial, participants who switched from semaglutide to placebo at 20 weeks regained approximately two-thirds of their lost weight within a year.

The practical implication: if you've plateaued, the answer is rarely to stop. It is almost always to adjust.

Evidence-Based Responses to a GLP-1 Plateau

1. Review Dose and Timing

The first question worth asking with your prescriber is whether your current dose is optimal. Both semaglutide and tirzepatide are titrated upward over time precisely because higher doses produce greater weight loss in most people. If you plateaued at 1.0mg and haven't tried 1.7mg or 2.4mg, there may be meaningful headroom.

This is a clinical conversation, not a self-prescription decision. But it's worth raising. Many people stay on a lower dose indefinitely because it felt adequate initially, without exploring whether titrating further would break the plateau.

2. Audit Diet Quality, Not Just Quantity

GLP-1 medications reduce appetite substantially. What they don't do is curate what you eat within that reduced appetite. It's entirely possible to eat 1,400 calories of foods that undermine weight loss: highly palatable ultra-processed foods that bypass satiety signalling, inadequate protein that leads to muscle loss rather than fat loss, or low fibre intake that slows gut transit and worsens constipation.

A plateau is a good moment to log food properly for one week, not to punish yourself, but to see the data. Most people find two or three specific adjustments that make a real difference.

Key dietary levers at plateau:

• Protein: minimum 1.6g per kg of body weight daily (see our complete GLP-1 protein guide)
• Fibre: 25-30g daily to support gut health and satiety
• Alcohol: a meaningful suppressor of fat oxidation, worth reducing or eliminating
• Ultra-processed foods: often high in fat and sugar combinations that override satiety even on GLP-1

Read our clean eating on GLP-1 guide for practical meal frameworks that support fat loss rather than working against it.

3. Add or Intensify Resistance Training

Cardio burns calories during exercise. Resistance training increases your resting metabolic rate by building lean muscle, which partly counteracts the adaptive thermogenesis effect described above. This makes it the most metabolically strategic form of exercise at plateau.

Two to three sessions per week of progressive resistance training is the evidence-backed minimum. If you're not currently lifting, starting now will produce measurable changes in body composition over 8-12 weeks, even if the scale doesn't immediately reflect it.

The Wegovy exercise plan covers exactly how to structure this.

4. Consider Coaching Support

Some plateaus are genuinely behavioural rather than physiological. Medication-induced appetite suppression can create a false sense that the work is done, leading to gradual drift in dietary habits that are hard to see from the inside.

Structured coaching, with someone who understands GLP-1 pharmacology and nutrition, can identify specific changes that move the needle. Lola Health offers clinical coaching alongside prescribing, specifically designed for the plateau phase.

What Not to Do at Plateau

Don't Stop the Medication

Stopping semaglutide at plateau typically leads to rapid weight regain within 3-6 months, as demonstrated repeatedly in discontinuation studies. The plateau is a slowdown, not a signal to stop.

Don't Dramatically Cut Calories Further

If you're already eating at a significant deficit, cutting further often accelerates muscle loss, worsens fatigue, and triggers further adaptive thermogenesis. Below roughly 1,200 kcal for women, the metabolic adaptation can outpace any additional calorie reduction. This is counterproductive.

Don't Increase Your Own Dose

Adjusting dosing without clinical oversight carries risks: increased nausea and vomiting, pancreatitis risk at very high doses, and inconsistent pharmacokinetics from non-standard dosing intervals. Any dose change should go through your prescriber.

Don't Compare Your Timeline to Others

Individual variation in GLP-1 response is substantial. Genetic differences in GLP-1 receptor expression, gut microbiome composition, baseline metabolic rate, and medication adherence all affect how quickly plateau is reached and how much additional loss is achievable.

Tracking Progress Beyond the Scale

One reason plateaus feel more frustrating than they need to is that the scale is the only metric most people track. During a weight plateau, meaningful changes are often still occurring:

• Body composition: You may be losing fat and gaining muscle simultaneously, producing no net change on the scale but significant improvements in body composition
• Waist circumference: Visceral fat (the metabolically active fat around organs) continues to reduce even during scale plateaus
• Metabolic markers: Blood glucose, insulin resistance, blood pressure, and lipid profiles may continue improving

Consider tracking waist measurements monthly and, if accessible, periodic HbA1c and lipid checks. For guidance on baseline metabolic testing, the GLP-1 blood tests guide covers what to request.

When Plateau Signals Something Else

Occasionally, a plateau does indicate something worth investigating medically:

• Thyroid dysfunction: Hypothyroidism reduces metabolic rate significantly. If you haven't had your thyroid checked recently, it's worth doing.
• Insulin resistance: Very high baseline insulin resistance can blunt GLP-1 response. This is more common in PCOS. See our GLP-1 and PCOS guide for detail.
• Sleep disorders: Untreated sleep apnoea or poor sleep quality significantly impair fat loss through cortisol dysregulation and appetite hormone disruption.

If your plateau has lasted more than 12 weeks without any movement in weight or body composition, and you've addressed the dietary and exercise variables, a conversation with your prescriber about investigation is appropriate.

The Bottom Line

A GLP-1 plateau is not a failure. It is a predictable biological response that occurs in almost every person on long-term GLP-1 therapy. The STEP trials showed us it happens around months 6-16. They also showed that continuing treatment, optimising protein and diet quality, and adding resistance training are the three most evidence-backed responses.

The medication hasn't stopped working. Your biology has adapted. Now you adapt back.

For more on making GLP-1 medications work long-term, see our first month on GLP-1 guide and the complete guide to GLP-1 side effects.